A day after announcing an agreement with a Chinese firm to develop and commercialize a new drug cocktail treatment for chronic hepatitis C, TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) provided more details of the link-up.
TaiGen and YiChang HEC ChangJiang Pharmaceutical Co Ltd (HEC, 宜昌東陽光長江藥業) have agreed to establish a joint venture to produce a treatment cocktail of two oral direct-acting antiviral agents (DAA) — TaiGen’s furaprevir (TG-2349), a NS3/4A protease inhibitor, and HEC’s yimitasvir (DAG-181), a NS 5 protein inhibitor.
The joint venture is to be established before the end of this year with capitalization of 680 million yuan (US$102 million), of which 348.4 million yuan would be provided by HEC in cash in exchange for a 51 percent stake.
TaiGen will receive a 49 percent stake for its licensing rights to TG-2349, which is appraised at about US$50 million, company officials said yesterday at a news conference in Taipei.
The company is expecting to book profits of US$20 million for its 49 percent stake before the second half of next year, TaiGen vice president of finance Richard Lu (呂理堅) said.
The agreement also stipulates that when the new cocktail completes its second-phase clinical trials in China, TaiGen would sell a 9 percent-portion of its stake in the joint venture to HEC for about another US$40 million, Lu added.
However, the conditions for the US$40 million sale would be contingent upon whether the new cocktail is able to achieve a sustained viral response rate of more than 90 percent in its second-phase study, Lu said.
The new cocktail has received fast-track review designation from Chinese regulators, and is scheduled to hit the market in two to three years, TaiGen chief operating officer Hsu Ming-chu (許明珠) said.
The outcome of scientific due diligence and animal testing on drug-to-drug interactions combining TG-2349 and DAG-181 have been favorable, Hsu said.
“We were approached by HEC last May to explore a partnership and we found the company to be a capable partner in terms of funding as well as the viability of its new drug,” Hsu said, adding that TaiGen had rejected a number of prospective candidates.
The joint venture will allow TaiGen to begin commercializing new drugs earlier in the development phase. In the past its revenue streams came from out-licensing its late-stage development drugs.
Currently available DAA treatments for hepatitis C can cost as much as US$90,000 for a 12-week regimen, but the joint venture’s new drug would be priced significantly lower, Hsu said.
The lower pricing, and the enlisting of a Chinese partner represent an advantage in gaining approval from Beijing regulators, who are looking to control China’s healthcare costs and improve access to treatments, Hsu said.
POWERING UP: PSUs for AI servers made up about 50% of Delta’s total server PSU revenue during the first three quarters of last year, the company said Power supply and electronic components maker Delta Electronics Inc (台達電) reported record-high revenue of NT$161.61 billion (US$5.11 billion) for last quarter and said it remains positive about this quarter. Last quarter’s figure was up 7.6 percent from the previous quarter and 41.51 percent higher than a year earlier, and largely in line with Yuanta Securities Investment Consulting Co’s (元大投顧) forecast of NT$160 billion. Delta’s annual revenue last year rose 31.76 percent year-on-year to NT$554.89 billion, also a record high for the company. Its strong performance reflected continued demand for high-performance power solutions and advanced liquid-cooling products used in artificial intelligence (AI) data centers,
SIZE MATTERS: TSMC started phasing out 8-inch wafer production last year, while Samsung is more aggressively retiring 8-inch capacity, TrendForce said Chipmakers are expected to raise prices of 8-inch wafers by up to 20 percent this year on concern over supply constraints as major contract chipmakers Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and Samsung Electronics Co gradually retire less advanced wafer capacity, TrendForce Corp (集邦科技) said yesterday. It is the first significant across-the-board price hike since a global semiconductor correction in 2023, the Taipei-based market researcher said in a report. Global 8-inch wafer capacity slid 0.3 percent year-on-year last year, although 8-inch wafer prices still hovered at relatively stable levels throughout the year, TrendForce said. The downward trend is expected to continue this year,
A proposed billionaires’ tax in California has ignited a political uproar in Silicon Valley, with tech titans threatening to leave the state while California Governor Gavin Newsom of the Democratic Party maneuvers to defeat a levy that he fears would lead to an exodus of wealth. A technology mecca, California has more billionaires than any other US state — a few hundred, by some estimates. About half its personal income tax revenue, a financial backbone in the nearly US$350 billion budget, comes from the top 1 percent of earners. A large healthcare union is attempting to place a proposal before
Vincent Wei led fellow Singaporean farmers around an empty Malaysian plot, laying out plans for a greenhouse and rows of leafy vegetables. What he pitched was not just space for crops, but a lifeline for growers struggling to make ends meet in a city-state with high prices and little vacant land. The future agriculture hub is part of a joint special economic zone launched last year by the two neighbors, expected to cost US$123 million and produce 10,000 tonnes of fresh produce annually. It is attracting Singaporean farmers with promises of cheaper land, labor and energy just over the border.
RSS